Trial NCT03860844

View at ClinicalTrials.gov 
Org. Study IDs: ACT15378
Secondary IDs: 2018-002697-45 2018-002697-45 U1111-1202-1096

Last trial update was posted on 2023-11-15

MeSH Interventions

Asparaginase Cyclophosphamide Cytarabine Daunorubicin Dexamethasone Doxorubicin Etoposide Fludarabine Hydroxyurea Idarubicin Methotrexate Mitoxantrone Pegaspargase Vincristine

MeSH Conditions

Leukemia Leukemia, Lymphoid Leukemia, Myeloid Leukemia, Myeloid, Acute Precursor Cell Lymphoblastic Leukemia-Lymphoma

Other Conditions

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia

Stopping Reasons

Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns.

Limitations And Caveats

The study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met) and not due to safety concerns.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID